Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer - PubMed (original) (raw)
Review
Third annual William L. McGuire Memorial Lecture. "Studies on the estrogen receptor in breast cancer"--20 years as a target for the treatment and prevention of cancer
V C Jordan. Breast Cancer Res Treat. 1995.
Abstract
In 1973, McGuire and Chamness (In: O'Malley BW and Means AR (ed) Receptors for Reproductive Hormones, Plenum Press) summarized their work on the estrogen receptor in animal and human breast tumors, and in so doing described a target for therapeutic intervention. At that time there were no clinically useful antiestrogens, but the subsequent development of tamoxifen for breast cancer therapy has revolutionized the approach to treatment. Long-term adjuvant tamoxifen adjuvant therapy (i.e., greater than one year) has proven efficacy to enhance the survival of breast cancer patients. In addition, because there is an associated 40% decrease in contralateral breast cancer during adjuvant tamoxifen therapy and tamoxifen maintains bone density and reduces fatal myocardial infarction, clinical trials to test the worth of tamoxifen as a preventive for breast cancer in high risk women have started in the United States, United Kingdom, and Italy. Initial concerns that long-term tamoxifen causes endometrial cancer have been placed in perspective and analyzed by a review of the literature. Tamoxifen only doubles the normal risk of detecting endometrial cancer (i.e., to 2 per 1,000 tamoxifen-treated women per year), and 80% of these cases are early stage, good prognosis disease. Annual gynecological examinations and education are essential to provide reassurance for patients. The success of tamoxifen has encouraged the development of new antiestrogens to exploit the estrogen receptor as a therapeutic target. Droloxifene and TAT-59 mimic the metabolite 4-hydroxytamoxifen in having a high affinity for the estrogen receptor (Jordan et al, J Endocrinol 75:305, 1977). These drugs appear to have a pharmacological profile similar to tamoxifen. In contrast, the new pure antiestrogens have a distinct mechanism of action and will be valuable either as a first line therapy for advanced breast cancer or as a second line endocrine therapy after the failure of long-term adjuvant tamoxifen therapy. Finally, a new strategy is being developed to exploit the target site specific action of antiestrogens. Raloxifene, an antiestrogen with high affinity for the estrogen receptor but only weak estrogenicity for the uterus, prevents rat mammary tumorigenesis and maintains bone density. The drug is to be evaluated as a treatment for osteoporosis, but may also prevent the development of breast and endometrial cancer in a broad group of treated subjects. The identification of the estrogen receptor as a target for therapeutic opportunities has proved to be extremely beneficial for the control of breast cancer and has the added potential to control osteoporosis and coronary heart disease in women.
Similar articles
- Selective estrogen receptor modulation: the search for an ideal hormonal therapy for breast cancer.
Dhingra K. Dhingra K. Cancer Invest. 2001;19(6):649-59. doi: 10.1081/cnv-100104293. Cancer Invest. 2001. PMID: 11486708 Review. - Basic guide to the mechanisms of antiestrogen action.
MacGregor JI, Jordan VC. MacGregor JI, et al. Pharmacol Rev. 1998 Jun;50(2):151-96. Pharmacol Rev. 1998. PMID: 9647865 Review. - Alternate antiestrogens and approaches to the prevention of breast cancer.
Jordan VC. Jordan VC. J Cell Biochem Suppl. 1995;22:51-7. doi: 10.1002/jcb.240590808. J Cell Biochem Suppl. 1995. PMID: 8538210 Review. - Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC, O'Regan RM, Gajdos C, Robinson SP, Bentrem D, De Los Reyes A, Jordan VC. Dardes RC, et al. Clin Cancer Res. 2002 Jun;8(6):1995-2001. Clin Cancer Res. 2002. PMID: 12060645 - The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer.
Howell SJ, Johnston SR, Howell A. Howell SJ, et al. Best Pract Res Clin Endocrinol Metab. 2004 Mar;18(1):47-66. doi: 10.1016/j.beem.2003.08.002. Best Pract Res Clin Endocrinol Metab. 2004. PMID: 14687597 Review.
Cited by
- Update Breast Cancer 2021 Part 5 - Advanced Breast Cancer.
Lüftner D, Schütz F, Stickeler E, Fasching PA, Janni W, Kolberg-Liedtke C, Kolberg HC, Thomssen C, Müller V, Fehm TN, Belleville E, Bader S, Untch M, Welslau M, Thill M, Tesch H, Ditsch N, Lux MP, Wöckel A, Aktas B, Schneeweiss A, Würstlein R, Hartkopf AD. Lüftner D, et al. Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):215-225. doi: 10.1055/a-1724-9569. eCollection 2022 Feb. Geburtshilfe Frauenheilkd. 2022. PMID: 35169389 Free PMC article. - IFI27/ISG12 Downregulates Estrogen Receptor α Transactivation by Facilitating Its Interaction With CRM1/XPO1 in Breast Cancer Cells.
Cervantes-Badillo MG, Paredes-Villa A, Gómez-Romero V, Cervantes-Roldán R, Arias-Romero LE, Villamar-Cruz O, González-Montiel M, Barrios-García T, Cabrera-Quintero AJ, Rodríguez-Gómez G, Cancino-Villeda L, Zentella-Dehesa A, León-Del-Río A. Cervantes-Badillo MG, et al. Front Endocrinol (Lausanne). 2020 Oct 7;11:568375. doi: 10.3389/fendo.2020.568375. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33117284 Free PMC article. - An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
Sun G, Wang C, Wang S, Sun H, Zeng K, Zou R, Lin L, Liu W, Sun N, Song H, Liu W, Zhou T, Jin F, Shan Z, Zhao Y. Sun G, et al. Nucleic Acids Res. 2020 Nov 4;48(19):10768-10784. doi: 10.1093/nar/gkaa787. Nucleic Acids Res. 2020. PMID: 32986841 Free PMC article. - Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Yang J, Harris AL, Davidoff AM. Yang J, et al. Int J Mol Sci. 2018 Jan 13;19(1):240. doi: 10.3390/ijms19010240. Int J Mol Sci. 2018. PMID: 29342868 Free PMC article. Review. - Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
Chen IC, Hsiao LP, Huang IW, Yu HC, Yeh LC, Lin CH, Wei-Wu Chen T, Cheng AL, Lu YS. Chen IC, et al. Sci Rep. 2017 Aug 29;7(1):9842. doi: 10.1038/s41598-017-10555-z. Sci Rep. 2017. PMID: 28852212 Free PMC article.
References
- Cancer Res. 1989 Sep 1;49(17):4765-9 - PubMed
- Br Med J. 1971 Jan 16;1(5741):152-4 - PubMed
- Eur J Cancer. 1975 Mar;11(3):205-6 - PubMed
- J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 - PubMed
- Proc Soc Exp Biol Med. 1960 Oct;105:197-201 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials